Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer
2004-000629-32Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by University of Oxford. Primary endpoint: Disease-free survival. Started Jan 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2004-000629-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000629-32.